Waheed Qaisi

Waheed Qaisi

Auto-generated profile, based on publicly available information

Waheed Qaisi

Department of Medicine, An-najah National University Faculty of Medicine and Health Sciences, Nablus, Palestine

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2025 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
MHMohamed Fawzi Hemida
Mohamed Fawzi Hemida
AMAlyaa Ahmed Ahmed Ibrahim Mohamed
Alyaa Ahmed Ahmed Ibrahim Mohamed
Zahin ShahriarZahin Shahriar
Zahin Shahriar
MKMaliha Khalid
Maliha Khalid
NZNafila Zeeshan
Nafila Zeeshan
RARaheel Ahmed
Raheel Ahmed

22 April 2026 in Clinical Medicine Insights: Endocrinology and Diabetes
Verified
Journal Article
Open access
ZEZiad W. Elmezayen
Ziad W. Elmezayen
FQFarah Qrareya
Farah Qrareya
AAAbdallah Abdallah
Abdallah Abdallah
HSHossam Salameh
Hossam Salameh
WQWaheed Qaisi
Waheed Qaisi
Euthyroid sick syndrome (ESS) is characterized by abnormal thyroid function tests, most notably a low triiodothyronine (T3) level, occurring in the absence of intrinsic thyroid disease. A 54-year-old woman presented to the endocrinology clinic with a 4-month history of progressive fatigue, lethargy, and new-onset cold intolerance after initiation of semaglutide for weight management. The dose was titrated monthly over 4 months, during which she experienced significant weight loss of 22 kg. Laboratory evaluation revealed a thyroid function profile classic for ESS, with low free T3, low-normal free T4, and a normal thyroid-stimulating hormone (TSH) level that was inappropriately low relative to the reduced T3. After exclusion of primary thyroid and pituitary disorders, a diagnosis of ESS secondary to the catabolic state induced by rapid weight loss was made. The patient was counseled that this represented a physiological adaptation rather than intrinsic thyroid disease. Semaglutide was continued given its metabolic benefits, and nutritional optimization with adequate caloric and protein intake was advised.